Diagnosis and Treatment of Cutaneous Adverse Effects of Targeted Therapy, Antibody-Drug Conjugates, and Immunotherapy in Cancer Patients: A National Consensus Statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology

January 2026 in “ Clinical & Translational Oncology ”

Margarita Majem, Kevin Molina Mata, Ander Mayor Ibarguren, Marta Zafra Poves, Celia Requena, Francisco de Asis Aparisi Aparisi, C. Carrera, Ana Blasco, Azael Freites‐Martínez, Onofre Sanmartín

From the encyclopedia

Minoxidil →

An essential vasodilator with some anti-androgenic effects

Platelet-Rich Plasma →

growth factors taken from your blood and injected into your scalp to stimulate hair

Studysummary This expert consensus statement highlights that while targeted cancer therapies significantly improve patient survival, they often result in various skin toxicities, underscoring the need for early diagnosis, management, and multidisciplinary care to maintain patients' quality of life and ensure treatment continuity.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

Platelet-Rich Plasma Treatment for Endocrine-Induced Alopecia and Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors: A Randomized, Controlled, Pilot Study

research Platelet-Rich Plasma Treatment for Endocrine-Induced Alopecia and Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors: A Randomized, Controlled, Pilot Study

July 2025 in “Dermatologic Surgery”

This study found that PRP may increase hair density in breast cancer survivors with EIA or pCIA, but improvements did not differ statistically between treated and untreated sides.

Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study

research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study

1 citations , July 2023 in “Cancers”

In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.

research Prevention And Management Of Dermatological Toxicities Related To Anticancer Agents: ESMO Clinical Practice Guidelines

86 citations , November 2020 in “Annals of Oncology”

These guidelines discuss prevention and management strategies for dermatological toxicities but report no new clinical results; they include expert recommendations for conditions like acneiform rash and hand-foot syndrome.

research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

179 citations , October 2018 in “American Journal of Clinical Dermatology”

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

research Hair Disorders in Patients with Cancer

53 citations , April 2018 in “Journal of The American Academy of Dermatology”

This article reviews therapy-related hair disorders in oncology patients, detailing underlying mechanisms and potential management strategies, but reports no new clinical findings.

research Skin Manifestations of Targeted Antineoplastic Therapy

8 citations , November 2017 in “Current problems in dermatology”

This review discusses the cutaneous side effects of targeted anticancer therapies, such as rashes and hair changes, but presents no new clinical results.

research Hair and Nail Adverse Events During Treatment with Targeted Therapies for Metastatic Melanoma

32 citations , May 2016 in “European journal of dermatology/EJD. European journal of dermatology”

In this study, researchers found that targeted therapies for metastatic melanoma often cause hair and nail side effects, with hair changes more common in patients treated with BRAF inhibitors like vemurafenib.

research Cutaneous Adverse Effects of Targeted Therapies

192 citations , January 2015 in “Journal of the American Academy of Dermatology”

This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.

Chemotherapy-Induced Dermatological Toxicity: Frequencies and Impact on Quality of Life in Women’s Cancers. Results of a Prospective Study

research Chemotherapy-Induced Dermatological Toxicity: Frequencies and Impact on Quality of Life in Women’s Cancers. Results of a Prospective Study

76 citations , August 2007 in “Supportive care in cancer”

The researchers reported that dermatological side effects from chemotherapy for women's cancers are common and significantly affect quality of life.